Inactive Instrument

Venn Life Sciences Holdings London S.E.

Equities

GB00B9275X97

Biotechnology & Medical Research

Venn Life Sciences : Change of Adviser

January 25, 2018 at 12:44 pm IST

25 January 2018

Venn Life Sciences Holdings plc

('Venn' or the 'Company' or the 'Group')

Appointment of Nominated Adviser and Broker

Venn Life Sciences Holdings plc, the AIM drug development services organisation, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.

Enquiries:

Venn Life Sciences Holdings plc	www.vennlifesciences.com
Allan Wood, Non-Executive Chairman	Tel: +44 (0)7785 325 898
Tony Richardson, Chief Executive Officer	Tel: +353 1 5499341

Cenkos (Nominated Adviser and Broker)	Tel: +44(0)20 7397 8900
Mark Connelly/Steve Cox (Corporate Finance)

Davy (ESM Adviser and Broker)	Tel: +353 1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)

Hybridan LLP ( Joint Broker)	Tel: +44 (0)20 3764 2341
Claire Louise Noyce

About Venn Life Sciences:Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences is available on their website - www.vennlifesciences.com

Venn Life Sciences Holdings plc published this content on 25 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2018 07:14:08 UTC.

Original documenthttp://irpages2.equitystory.com/websites/rns_news/English/1100/news-tool---rns---eqs-group.html?article=26975435&company=vennlife

Public permalinkhttp://www.publicnow.com/view/008BFB6DF87D874F957E3F9E1A3DE776BE2A85CC

Latest news about Venn Life Sciences Holdings

HVIVO reports 31% revenue jump; relocation to improve efficiencies	17/07	AN
Transcript : HVIVO plc - Analyst/Investor Day	17/07
Creo extends contract; Belluscura raises funds	03/07	AN
HVIVO plc Announces Change of Registered Address	02/07	CI
HVIVO plc Announces Phase 2b Influenza Field Study Contract	02/07	CI
HVIVO says Omicron contract validates move to Canary Wharf facility	03/06	AN
HVIVO plc Signs £2.5 Million Contract with A Mid-Sized Pharmaceutical Company to Initiate an Omicron characterization study	03/06	CI
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	09/04
HVIVO swings to profit and commences annual dividends as outlook rosy	09/04	AN
HVIVO plc Provides Revenue Guidance for the Year 2024	09/04	CI
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	09/04
HVIVO plc Reports Earnings Results for the Full Year Ended December 31, 2023	09/04	CI
European Green Transition starts trading on London's AIM market	08/04	AN
Investment firm European Green Transition plans listing on AIM	18/03	AN
HVIVO Chair and non-exec director sell 30.0 million shares	15/02	AN
Hvivo Completes Secondary Placing	14/02	MT
HVIVO directors to sell total of 14 million shares	14/02	AN
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	14/02	MT
Transcript : HVIVO plc, Q4 2023 Sales/ Trading Statement Call, Jan 30, 2024	30/01
FTSE 100 Ends on Three-Week High, Partly on Diageo Rebound	30/01	DJ
HVIVO shares up after "record year" across all metrics	30/01	AN
Hvivo Wins GBP6 Million Antiviral Testing Contract	02/01	MT
HVIVO inks GBP6.3 million deal to test common cold treatment	02/01	AN
New Year begins largely green amid slew of PMIs	02/01	AN
HVIVO plc Signs £6.3 Million Human Challenge Study Model	02/01	CI

Chart Venn Life Sciences Holdings

Duration

Period

More charts

Company Profile

hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge trials in London with a new 50 quarantine bedroom, state-of-the-art facilities opening in Canary Wharf in 2024, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Sector

Biotechnology & Medical Research

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+48.49%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research